PPT-Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic

Management of HER2 OverExpressed Breast Cancer in the Adjuvant Neoadjuvant and Metastatic settings Christy A Russell MD Keck School of Medicine University of Southern California Metastatic Breast Cancer. First . Line and Beyond. Moderator:. Joseph Gligorov, MD, . PhD . Head, Cancer . Coordination Center . HUEP. University . Cancer . Institute. Sorbonne University. Paris. , . France. Panelist:. Carlos H. Barrios, . Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. An Interactive Oncology Grand Rounds Series. Joyce O’Shaughnessy, MD. Chair, Breast Cancer Research Program. Baylor Charles A Sammons Cancer Center. Celebrating Women Chair in Breast Cancer Research. Antonella Brunello . Kwok-Leung Cheung. Disclosure. No . conflict. of . interests. Learning objectives. To . discuss the pros and cons of adjuvant chemotherapy for breast cancer in the elderly. To . Triple-Negative Breast Cancer. Jamie Carroll, APRN, MSN, CNP. Hope S . Rugo. , MD. . Disclosures for . Ms. Carroll. No financial interests or affiliations to disclose. Disclosures for Dr . Rugo. Contracted Research. surgical resection versus organ preservation. Dr Jessica Jenkins. Consultant Oncologist. Background. The largest proportion of colorectal cancer cases occur in the rectum.. Each year in UK; over 8500 patients are diagnosed with Rectal Cancer.. Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Anne Sofie Brems-Eskildsen. Department of Oncology, University Hospital of Aarhus. Guidelines in . Oncology . for ILC follows IDC. ASCO . G. uidelines . for early breast cancer (not mentioned). St. . . . Breast Cancer | . Epidemiology- Australia. Australian Institute of Health and Welfare 2014. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra. AIHW. Overall is the third leading cause of cancer. Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca. Percent with Patients. Number of Patients (Median). ER-positive, HER2-negative breast cancer for whom you ordered a genomic assay. 92. 14. Metastatic ER-positive, HER2-negative . breast cancer. 96. 10. Jo Anne Zujewski, M.D.. June 2019. Thimphu. , Bhutan. Define the breast cancer. Is the cancer operable?. Stage 1: systemic therapy after surgery (and radiation if breast conservation). Stage 2: systemic therapy before or after therapy.